Chapter 7. Cardiovascular Toxicity of Antitumor Drugs: Translating Molecular Mechanisms into Clinical Facts

  1. Giorgio Minotti
  1. Pierantonio Menna2,
  2. Emanuela Salvatorelli2,
  3. Carlo Salsano2,
  4. Luca Gianni1 and
  5. Giorgio Minotti2

Published Online: 9 APR 2010

DOI: 10.1002/9780470660379.ch7

Cardiotoxicity of Non-Cardiovascular Drugs

Cardiotoxicity of Non-Cardiovascular Drugs

How to Cite

Menna, P., Salvatorelli, E., Salsano, C., Gianni, L. and Minotti, G. (2010) Cardiovascular Toxicity of Antitumor Drugs: Translating Molecular Mechanisms into Clinical Facts, in Cardiotoxicity of Non-Cardiovascular Drugs (ed G. Minotti), John Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/9780470660379.ch7

Editor Information

  1. University Campus Bio-Medico, CIR and Drug Sciences, and Alberto Sordi Foundation-Research Institute on Aging, Via Alvaro del Portillo 21, 00128 Rome, Italy

Author Information

  1. 1

    Istituto Nazionale Tumori, Via Venezian 1, 20133 Milan, Italy

  2. 2

    University Campus Bio-Medico, CIR and Drug Sciences, and Alberto Sordi Foundation-Research Institute on Aging, Via Alvaro del Portillo 21, 00128 Rome, Italy

Publication History

  1. Published Online: 9 APR 2010
  2. Published Print: 16 APR 2010

ISBN Information

Print ISBN: 9780470772744

Online ISBN: 9780470660379

SEARCH

Keywords:

  • antitumor drugs' cardiovascular toxicity - clinical facts;
  • antitumor drugs-induced cardiotoxicity - contemporary issues;
  • anthracyclins and cardiotoxicity preclinical models, improvements;
  • anthracycline cardiotoxicity mechanisms - metabolic determinants;
  • human heart translational model - clinical aspects and applications;
  • multiple-hit theory - integrated model and future aspects;
  • tastuzumab - predicting cardiotoxicity;
  • trastuzumab and Multiple-Hit hypothesis;
  • cardiotoxicity and targeted drugs, others

Summary

This chapter contains sections titled:

  • Contemporary Issues in Cardiotoxicity Induced by Antitumor Drugs

  • Of Models and Predictiveness: Lessons from Anthracyclines

  • Unfilled: The GAP from Translational Models for the Multiple-Hit Mechanism

  • Predicting Cardiotoxicity from Targeted Drugs: Lessons from Tastuzumab

  • Cardiotoxicity from other Targeted Drugs

  • Conclusions

  • References